IDH2 and central nervous system cancer: Isocitrate dehydrogenase (IDH)6,7 mutation status is a key genetic characteristic used to inform the prognosis and treatment of glioma patients.3,4,5,7,8 PsP affects both IDH mutant and wild-type glioma patients but has been poorly characterized in IDH mutant patients.